Simple Test Predicts Childhood Cancer Relapse
By LabMedica International staff writers Posted on 26 May 2016 |

Image: The IncuCyte zoom continuous live-cell imaging and analysis system (Photo courtesy of Essen Biosciences).
High-risk neuroblastoma, which occurs mostly in children under five, is treated with surgery and chemotherapy, and neuroblastomas currently rated low risk are just removed or left untreated while doctors 'wait and see', but a fraction of low risk tumors recur and ultimately kill.
A cheap simple test could accurately predict the recurrence of a childhood cancer, as a protein marker has been pinpointed which when absent, shows neuroblastoma is almost certain to recur. It means children with low-risk neuroblastoma, who do not have the biomarker, can be reclassified as at high risk of relapse and have chemotherapy earlier.
Scientists at Brunel University London (UK) and their colleagues collected a retrospective series of primary tumors from neuroblastoma (NB) patients. Formalin-fixed, paraffin-embedded tissue sections from NB tumors were studied. Each tumor area tested contained malignant cells, assessed by histological examination. Quantification of immunofluorescence- or DAB-positive tumor cells was performed on serial tumor tissue sections. Tumor cells were distinguished in the samples using NB-specific marker, the homophilic binding glycoprotein neural cell adhesion molecule (NCAM, CD56).
The scientists carried out cell proliferation assays using IncuCyte live-cell imaging system (Essen Biosciences, Ann Arbor, MI, USA); immunostaining of cultured cells; Western blotting; angiogenesis assays where the images were captured using JuLI smart fluorescent cell analyzer (Baker Ruskinn, Sanford, ME; USA). The investigators used several other methodologies to identify the Promyelocytic Leukaemia protein-1(PML-1) and gene expression was assessed using chip microarrays.
PML was detected in the developing and adult sympathetic nervous system, whereas it was not expressed or low in metastatic neuroblastoma tumors. Reduced PML expression in patients with low-risk cancers, i.e. localized and negative for the V-Myc Avian Myelocytomatosis Viral Oncogene Neuroblastoma Derived Homolog (MYCN) protooncogene was strongly associated with tumor recurrence. PML-I, but not PML-IV, isoform suppresses angiogenesis via upregulation of thrombospondin-2 (TSP-2), a key inhibitor of angiogenesis. Finally, PML-I and TSP-2 expression inversely correlates with tumor angiogenesis and recurrence in localized neuroblastomas.
Paolo Salomoni, PhD, a professor and senior author of the study said, “We have found the absence of PML a very precise marker of tumor recurrence. In the low risk tumors, the absence of PML will be a very useful marker. What we can now say is that even some tumors classified as low risk, that would have previously gone untreated, if they show no expression of PML, they ought now to be classified as high risk.” The study was published on April 13, 2016, in the journal Clinical Cancer Research.
Related Links:
Brunel University London
Essen Biosciences
Baker Ruskinn
A cheap simple test could accurately predict the recurrence of a childhood cancer, as a protein marker has been pinpointed which when absent, shows neuroblastoma is almost certain to recur. It means children with low-risk neuroblastoma, who do not have the biomarker, can be reclassified as at high risk of relapse and have chemotherapy earlier.
Scientists at Brunel University London (UK) and their colleagues collected a retrospective series of primary tumors from neuroblastoma (NB) patients. Formalin-fixed, paraffin-embedded tissue sections from NB tumors were studied. Each tumor area tested contained malignant cells, assessed by histological examination. Quantification of immunofluorescence- or DAB-positive tumor cells was performed on serial tumor tissue sections. Tumor cells were distinguished in the samples using NB-specific marker, the homophilic binding glycoprotein neural cell adhesion molecule (NCAM, CD56).
The scientists carried out cell proliferation assays using IncuCyte live-cell imaging system (Essen Biosciences, Ann Arbor, MI, USA); immunostaining of cultured cells; Western blotting; angiogenesis assays where the images were captured using JuLI smart fluorescent cell analyzer (Baker Ruskinn, Sanford, ME; USA). The investigators used several other methodologies to identify the Promyelocytic Leukaemia protein-1(PML-1) and gene expression was assessed using chip microarrays.
PML was detected in the developing and adult sympathetic nervous system, whereas it was not expressed or low in metastatic neuroblastoma tumors. Reduced PML expression in patients with low-risk cancers, i.e. localized and negative for the V-Myc Avian Myelocytomatosis Viral Oncogene Neuroblastoma Derived Homolog (MYCN) protooncogene was strongly associated with tumor recurrence. PML-I, but not PML-IV, isoform suppresses angiogenesis via upregulation of thrombospondin-2 (TSP-2), a key inhibitor of angiogenesis. Finally, PML-I and TSP-2 expression inversely correlates with tumor angiogenesis and recurrence in localized neuroblastomas.
Paolo Salomoni, PhD, a professor and senior author of the study said, “We have found the absence of PML a very precise marker of tumor recurrence. In the low risk tumors, the absence of PML will be a very useful marker. What we can now say is that even some tumors classified as low risk, that would have previously gone untreated, if they show no expression of PML, they ought now to be classified as high risk.” The study was published on April 13, 2016, in the journal Clinical Cancer Research.
Related Links:
Brunel University London
Essen Biosciences
Baker Ruskinn
Latest Pathology News
- AI Tool Accurately Determines Breast Cancer Prognosis
- Powerful New Tool Improves Tissue Cancer Analysis
- AI-Based Tool Measures Cancer Aggressiveness
- Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels
- New AI-Based Method Effectively Identifies Disease Phenotypes Using Light-Based Imaging
- AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care
- AI Tool Enhances Interpretation of Tissue Samples by Pathologists
- AI-Assisted Technique Tracks Cells Damaged from Injury, Aging and Disease
- Novel Fluorescent Probe Shows Potential in Precision Cancer Diagnostics and Fluorescence-Guided Surgery
- New Lab Model to Help Find Treatments for Aggressive Blood Cancer
- AI-Supported Microscopy Improves Detection of Intestinal Parasite Infections
- AI Performs Virtual Tissue Staining at Super-Resolution
- AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis
- Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response
- Clinical AI Solution for Automatic Breast Cancer Grading Improves Diagnostic Accuracy
- Saliva-Based Testing to Enable Early Detection of Cancer, Heart Disease or Parkinson’s
Channels
Clinical Chemistry
view channel
Skin Swabs Could Detect Parkinson’s Years Before Symptoms Appear
Parkinson’s disease is notoriously difficult to diagnose in its early stages, as motor symptoms do not appear until later in the progression of the disease. The ability to detect the disease up to seven... Read more
New Clinical Chemistry Analyzer Designed to Meet Growing Demands of Modern Labs
A new clinical chemistry analyzer is designed to provide outstanding performance and maximum efficiency, without compromising affordability, to meet the growing demands of modern laboratories.... Read more
New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
Nucleic acid amplification tests (NAATs) play a key role in diagnosing a wide range of infectious diseases. These tests are generally known for their high sensitivity and specificity, and they can be developed... Read moreMolecular Diagnostics
view channel
Highly Accurate Biomarkers Could Detect Ovarian Cancer Before Clinical Diagnosis
Ovarian cancer is a deadly and challenging disease, primarily because early detection is difficult. Most women (70-75%) are diagnosed only after the cancer has already spread, which significantly reduces... Read more
New Gene Tool to Enable Earlier Detection and Treatment of Cardiometabolic Diseases
Cardiometabolic diseases, which affect the heart, blood vessels, and the body's ability to process food and generate energy, are difficult to diagnose early due to the complex genetic changes that contribute... Read moreHematology
view channel
Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read moreImmunology
view channel
New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy
To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more
Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer
Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more
Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes
Diagnosing immune disruptions quickly and accurately is crucial in conditions such as sepsis, where timely intervention is critical for patient survival. Traditional testing methods can be slow, expensive,... Read moreMicrobiology
view channel
Early Detection of Gut Microbiota Metabolite Linked to Atherosclerosis Could Revolutionize Diagnosis
Cardiovascular disease is the leading cause of death worldwide, and atherosclerosis plays a critical role in its development. This chronic condition, characterized by the hardening and narrowing of arteries... Read more
Viral Load Tests Can Help Predict Mpox Severity
Mpox is a viral infection that causes flu-like symptoms and a characteristic rash, which evolves significantly over time and varies between patients. The disease spreads mainly through direct contact with... Read more
Gut Microbiota Analysis Enables Early and Non-Invasive Detection of Gestational Diabetes
Gestational diabetes mellitus is a common metabolic disorder marked by abnormal glucose metabolism during pregnancy, typically emerging in the mid to late stages. It significantly heightens the risk of... Read moreTechnology
view channel
Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells
A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Safer, Portable and Low-Cost Imaging Solution to Revolutionize Biomedical Diagnostics
In diagnosing diseases and monitoring treatment, accurate and quick detection of temperature within biological tissues can be crucial, especially in early disease detection. Conventional methods such as... Read more
Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation
Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read moreIndustry
view channel
QuidelOrtho and BÜHLMANN Collaborate on Gastrointestinal Biomarker Tests
QuidelOrtho Corporation (San Diego, CA, USA) and BÜHLMANN Laboratories AG (Schönenbuch, Switzerland) have announced the availability of the BÜHLMANN fCAL turbo and fPELA turbo assays on QuidelOrtho's... Read more